Metastatic Anal Cancer and Novel Agents
Authors:
- 1 January 2017
- journal article
- research article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 26 (1) , 133-142
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4Science, 2011
- Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of PersistenceJNCI: Journal of the National Cancer Institute, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of InfectionJNCI: Journal of the National Cancer Institute, 2010
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Tissue expression of PD-L1 mediates peripheral T cell toleranceJournal of Experimental Medicine, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004